Bloomberg Anywhere Remote Login Bloomberg Terminal Request a Demo

Bloomberg

Connecting decision makers to a dynamic network of information, people and ideas, Bloomberg quickly and accurately delivers business and financial information, news and insight around the world.

Company

Financial Products

Enterprise Products

Media

Customer Support

  • Americas

    +1 212 318 2000

  • Europe, Middle East, & Africa

    +44 20 7330 7500

  • Asia Pacific

    +65 6212 1000

Communications

Industry Products

Media Services

Follow Us


September 04, 2015 10:06 PM ET

Pharmaceuticals

Company Overview of ContraVir Pharmaceuticals, Inc.

Company Overview

ContraVir Pharmaceuticals, Inc. operates as a biopharmaceutical company focused on the discovery and development of targeted antiviral therapies. Its lead candidate, FV-100, is an orally available nucleoside analogue prodrug that is being developed for the treatment of herpes zoster, or shingles, which is an infection caused by the reactivation of varicella zoster virus. The company has completed Phase I trials of FV-100 in volunteers, as well as a Phase IIa clinical trial in shingles patients. It also plans to conduct a trial in patients with shingles to further explore FV-100's potential to treat the long-lasting nerve pain typically associated with shingles. The company was founded in 201...

399 Thornall Street

First Floor

Edison, NJ 08837

United States

Founded in 2013

3 Employees

Phone:

732-902-4000

Fax:

732-902-4100

Key Executives for ContraVir Pharmaceuticals, Inc.

Chief Executive Officer and Director
Age: 53
Total Annual Compensation: $86.2K
Chief Financial Officer
Age: 46
Total Annual Compensation: $4.9K
Compensation as of Fiscal Year 2014.

ContraVir Pharmaceuticals, Inc. Key Developments

ContraVir Pharmaceuticals, Inc. - Shareholder/Analyst Call

ContraVir Pharmaceuticals, Inc. - Shareholder/Analyst Call

ContraVir Pharmaceuticals, Inc. Presents at Virtual Investor Conference August 2015, Aug-06-2015 12:15 PM

ContraVir Pharmaceuticals, Inc. Presents at Virtual Investor Conference August 2015, Aug-06-2015 12:15 PM. Speakers: James E. Sapirstein, Chief Executive Officer and Director.

ContraVir Pharmaceuticals, Inc. Enrolls First Patient in Pivotal Phase 3 Study of FV-100 for Treatment of Shingles and Shingles-Associated Pain

ContraVir Pharmaceuticals, Inc. announced that the first patient has been enrolled in the company's pivotal Phase 3 clinical study, study 007, of FV-100 to prevent the debilitating shingles-associated pain known as post-herpetic neuralgia (PHN). The first patient in the study enrolled at Center for Clinical Studies in Houston, Texas. The study will build upon prior clinical results for FV-100, including Phase 1 trials and a large Phase 2 clinical trial in shingles patients, which demonstrated favorable safety and tolerability for FV-100. The pivotal study 007 will compare FV-100 to valacyclovir (Valtrex) with the reduction in the incidence of shingles-associated pain, PHN, as a primary endpoint. It is a multi-center, randomized, double-blind, parallel-group, comparative study in up to 200 centers in the U.S. The study is comprised of three arms: FV-100 400mg QD, FV-100 400mg BID, and valacyclovir 1000mg TID. Approximately 825 patients are expected to be analyzed for a seven-day treatment period, and follow up through day 120. FV-100 is a fast-acting, low-dose, oral antiviral therapy for treatment of herpes zoster, or shingles. In addition to its potent antiviral activity, FV-100 has demonstrated an ability to reduce the incidence and severity of debilitating shingles-associated pain, known as post-herpetic neuralgia, or PHN. In Phase 2 trials, FV-100 demonstrated a clinically meaningful 37% reduction in the incidence of PHN versus valacyclovir (Valtrex), and favorable safety and tolerability.

Similar Private Companies By Industry

Company Name Region
Nutramed, Inc. United States
WellSpring Pharmaceutical Corporation United States
Salient Pharmaceuticals Incorporated United States
Mist Pharmaceuticals, LLC United States
Dental Technologies, Inc. United States

Recent Private Companies Transactions

Type
Date
Target
Private Placement
February 26, 2015
--
Private Placement
October 14, 2014
--
 

Stock Quotes

Market data is delayed at least 15 minutes.

Company Lookup

Most Searched Private Companies

Company Name Geographic Region
Lawyers Committee for Civil Rights Under Law United States
Bertelsmann AG Europe
NYC2012, Inc. United States
Rush University United States
Citizens Budget Commission United States

Sponsored Financial Commentaries

Sponsored Links

Report Data Issue

To contact ContraVir Pharmaceuticals, Inc., please visit www.contravir.com. Company data is provided by Capital IQ. Please use this form to report any data issues.

Please enter your information in the following field(s):
Update Needed*

All data changes require verification from public sources. Please include the correct value or values and a source where we can verify.

Your requested update has been submitted

Our data partners will research the update request and update the information on this page if necessary. Research and follow-up could take several weeks. If you have questions, you can contact them at bwwebmaster@businessweek.com.